jhoxinvestor: Apparently you haven't been reading ALL the posts as there have been a number of rational responses to Adeifig's non-real world projections. In a nutshell VBLOC got approved because the approval bar for medical devices is much lower than for drugs and obesity is a very serious problem. Weight loss with VBLOC was fairly good, but the safety factor was a big plus. Opting for VBLOC is a major financial commitment and it still is surgery. Reputable bariatric surgeons will NOT oversell VBLOC to patients with false expectations. To think that VBLOC will crush the competition is fantasy. It has a place and $4 to $7 is probably the best we can hope for.
Ade: This is NOT your honest opinion. You are making the most lunatic TV evangelist look more grounded in reality than you!
I take encouragement from the fact that in the last few trading sessions ETRM has set a HIGHER intraday low. The shorts have had their day.
adeifligaro: VBLOC is a niche market governed by FDA guidelines. The nurse at Moore Metabolics lost 200 lbs through radical surgery. Only motivated patients terrified of surgery will try VBLOC.
As I posted the other day I expected ETRM to begin a price rise. The stock was way oversold and the company is starting to give more clarity.
Your projections have two important flaws: 1) Significant reimbursement won't happen in 12-18 months; 2) surgeons will only perform VBLOC on optimum candidates, constrained by FDA guidelines and the fairly modest weight loss. Surgeons will not perform VBLOC in uncontrolled huge numbers and risk patient ire and defaulting of loans for the surgery. Why do you think ETRM was only able to get on board a no-name financing source?
demesnedenoir: You hit the nail on the head. Ade must write those outrageous ads for sales positions that make impossible claims of earnings potential. I don't know how much longer I can avoid putting Ade on ignore. FYI, I do expect ETRM to continue an upward price movement.
Ade: Analyst consensus for 2016 is $8.7 million sales and .36 loss per share. Wake up from your dream or your deliberate disinformation campaign.
Inns: Dr Shikora is NOT giving up a lucrative medical practice. He may still be based In Boston. You would be amazed at how many senior executives and medical directors have multiple outside interests. I'm sure Dr Shikora will get some handsome stock options.
Hondo: Your post sounds like an exaggerated infomercial. Good results, but not spectacular, have been known for VBLOC for several years. Very very few fads materialize for a high cost item, such as VBOC(which by the way is NOT completely painless).
Is Knudson listening? (From FierceMedicalDevices)
Is Knudson listening?
A survey of the top 100 makers of medical devices in Asia indicates the industry will reach the $15 billion
mark in 2017, a huge leap from a market of just $2 billion in 2012.
In addition to the top 100, Research and Markets also focused individually on the device markets in India, Japan and South Korea, all three major ones. Japan, in fact, has the second largest in the world, behind only the United States.
As for Asia, the research company said the overall device market was growing by more than 10% a year to meet the demand driven by higher incomes and living standards in several of the leading countries on the continent.
In Japan, the device market is expected to increase by a compound annual growth rate of 2.9%, its value rising from $30.2 billion just two years ago to $34.9 billion in 2018.
South Korea has Asia's third largest market for devices, behind Japan and China, but is expected to expand by a compound rate of 7.7% by 2018, up from $5.1 billion in 2013.
The small stock price and volume boosts from Monday and Tuesday's press releases appear to be melting. Most frustrating is that the intraday high has fallen in the last three trading sessions from 1.09 to 1.07 to 1.04; ETRM needs a European and/or Asian partner to infuse some cash.
We should close modestly green today; however, I expect one last attempt to knock down the share price before the close. Innsbrooklad: you need to work on your reading comprehension-I said "rumor". The market lives on rumors, most of which turn out to be false.
Another takeout just announced: Mylan buying Perrigo. 2014 was a record M & A year in pharma. ETRM is way overdue for rumors that could double or triple the stock price.
I almost posted a couple of days ago that I thought we had reached bottom after Thursday's debacle: the unremitting downward stock price spiral was bound to self correct. I think management may now be laying out the bait for a partnership. Too many pharmas worldwide have many billions of excess cash.
Ade: You make old-time carnival barkers blush at your silver-tongued hallucinations. Analysts consensus on E-Trade estimate per share losses of .36, .33 and .28 for the years 2016-2018. You think that reimbursement money grows on trees and ETRM's rollout expenses are low. Wrong on both counts.
Ade: As usual you are in fantasyland. Until there is significant reimbursement by insurers bariatric surgeons will only cherry pick affluent customers, or the few who will finance. The main reason? Quite a few potential patients will have exaggerated expectations of their weight loss potential with VBLOC and a bill medical bill only adds to patient dissatisfaction. Probably the main reason ETRM could not snare a bigger finance entity like Care Credit: The necessity of a large loan to the patient and the probability of a fairly high default rate.
Ade: You keep repeating THE BIG LIE about VBLOC's so-called monopoly/dominant position. Fact check: VBLOC squeaked through with FDA approval; many bariatric surgeons will hesitate to employ VBLOC because of high cost and fairly moderate weight loss, UNTIL significant reimbursement happens, VBLOC's sales will probably be in line with analyst estimates: $1.5M in 2015, $8.7M in 2016, $30.8M in 2017, $53.1M in 2018, with NO analysts predicting a profit for any of those years. Every estimate you have made, especially regarding the share price, has been balderdash.